Are you A Sysa-Jędrzejowska?

Claim your profile

Publications (2)4.86 Total impact

  • Source
    Article: Prevalence of nonspecific cutaneous vascular lesions and association with antiphospholipid antibodies in patients with systemic lupus erythematosus.
    T Hawro, M Maurer, A Sysa-Jędrzejowska, A Woźniacka
    [show abstract] [hide abstract]
    ABSTRACT: Lupus nonspecific vascular skin lesions are widely expressed in systemic lupus erythematosus (SLE) but found also in other diseases. Their distribution, prevalence and association with antiphospholipid antibodies in SLE remain to be characterized in detail. Underlying vasculitic or thromboembolic pathology are considered.(1) The aim of the study was to evaluate clinical correlations of lupus nonspecific vascular skin manifestations in SLE patients and to investigate the relationship between particular skin lesions of vascular type and antiphospholipid antibodies.
    British Journal of Dermatology 05/2012; · 3.67 Impact Factor
  • Source
    Article: Topical application of NADH for the treatment of rosacea and contact dermatitis
    A. Woźniacka, A. Sysa-Jędrzejowska, J. Adamus, J. Gębicki
    [show abstract] [hide abstract]
    ABSTRACT: Among many important physiological functions played by NADH (the reduced form of β-nicotinamide adenine dinucleotide) its antioxidative properties are remarkable. Acting directly as an antioxidant, NADH can effectively protect the cell and its membrane from destruction by free radicals. NADH can be stabilized as a suspension in hydrophobic ointments prepared in a way that prevents contact with atmosphere containing oxygen and water. We present the first report of NADH as a treatment for some inflammatory dermatoses. It was found that topical application of 1% NADH diluted in Vaseline ointment can be very effective in the treatment of rosacea and contact dermatitis. Since no adverse effects were observed, therapy with NADH can be viewed as a potential alternative to other established treatments.
    Clinical and Experimental Dermatology 12/2002; 28(1):61 - 63. · 1.20 Impact Factor